Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRNX
CRNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRNX News
Crinetics Presents Phase 2 Data for Atumelnant at ENDO 2026
5d ago
NASDAQ.COM
Crinetics' Atumelnant Significantly Reduces Androgens in CAH Treatment
5d ago
Newsfilter
PALSONIFY Shows Long-Term Efficacy in Acromegaly at ENDO 2026
5d ago
Newsfilter
Crinetics Releases Long-Term Data on PALSONIFY for Acromegaly
5d ago
Yahoo Finance
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
Jun 02 2026
Newsfilter
Crinetics Presents New Data on PALSONIFY™ at ENDO 2026
Jun 02 2026
Yahoo Finance
ADAR1 Capital Increases Stake in Crinetics Pharmaceuticals
May 18 2026
Fool
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
May 08 2026
seekingalpha
Crinetics Pharmaceuticals: Stock Potential Analysis
May 02 2026
Yahoo Finance
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
Crinetics' PALSONIFY Receives EU Approval for Acromegaly Treatment
Apr 28 2026
NASDAQ.COM
PALSONIFY Approved in EU for Acromegaly Treatment
Apr 27 2026
Newsfilter
Neutrolis Appoints New Chief Business & Strategy Officer
Apr 15 2026
Globenewswire
Neutrolis Appoints New Chief Business Officer
Apr 15 2026
Newsfilter
Crinetics (CRNX.US) Officer Plans to Sell $3.27 Million in Common Stock via Form 144
Apr 08 2026
moomoo
Crinetics Pharmaceuticals Director Sells Shares
Mar 28 2026
NASDAQ.COM
Show More News
